Foley Hoag Represents Pervasis Therapeutics in Deal With Shire
April 24, 2012
Foley Hoag LLP represented Pervasis Therapeutics in connection with a sale of substantially all of Pervasis’ assets to a subsidiary of Shire plc.
The deal provided Pervasis with an upfront payment, plus potential post-closing payments that are dependent on Shire’s achievement of certain clinical-development, regulatory and net-sales milestones. The U.K.-based Shire acquired Pervasis’ lead product Vascugel, which is currently in Phase 2 development for acute vascular repair, focused on improving hemodialysis access for patients with end-stage renal disease.
About Foley Hoag LLP
Foley Hoag is a dynamic law firm that represents public and private clients in a wide range of disputes and transactions worldwide. We have expertise in industries such as life sciences and healthcare, technology, energy and cleantech, investment management, and professional services. We also offer our clients market-leading international litigation and arbitration and corporate social responsibility services. From our offices in Boston, Washington, D.C. and Paris, we provide strategic legal advice that is tailored to each of our client’s unique goals. Foley Hoag combines powerful regional, national and international practices that share a common emphasis on client service. We are focused on what we do best: helping our clients succeed through the delivery of exceptional legal service. For more information, visit www.foleyhoag.com